Biogen Inc (BIIB)

Explore Biogen Inc (BIIB) share price insights and analysis for better trading decisions. Stay informed with FP Markets Turkey for expert share price updates.

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

Biogen Inc (BIIB) Profile

Biogen Inc (BIIB.xnas) is a multinational biotechnology company and pioneers in neuroscience headquartered in Massachusetts, America. Biogen specialises in the discovery, development, and delivery of therapies to treat neurological diseases to patients globally with marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA, FUMADERM and SPINRAZA. Biogen is the first company that FDA approved Biogen’s Alzheimer’s disease drug aducanumab, which U.S. regulators cleared to slow cognitive decline in people living with the disease. Biogen is one of the world’s first global biotechnology companies aiming the last decade to defeat devastating neurological diseases with 38 office locations across 33 countries. The company operates outside of the United States, across Europe, Canada, Latin America, the Middle East and the Asia Pacific and employs 9.100 people. Biogen has a network of distribution partners in over 50 additional countries with 42 subsidiaries and a $13.4B (USD) in 2020 yearly revenue. The Biogen Inc stock (BIIB.xnas) is traded on the NASDAQ and has a market capitalisation of $32.92B (USD) as of December 2021. The U.S regulators approved Biogen’s aducanumab drug to treat Alzheimer in June 2021 with the price of $56,000 (USD) per year.

Start Trading Biogen Inc (BIIB) with a Market Leader Today

Biogen Inc (BIIB) Trading FAQ

Shares represent units of ownership within a company. Shares are also known as stocks or equities. Dividend payments are common with some companies, a method of sharing company profits with shareholders. In addition to traditional share dealing, however, traders can access derivatives: trading instruments derived from the movement of an underlying share price.

Individual stock CFDs (contract for differences) fall under the umbrella of derivative products, an effective low-cost trading vehicle. While CFDs do not grant shareholder privileges, active CFD positions may receive a dividend if executed before the ex-dividend date.

Start Trading
in minutes

Get instant Updates in Telegram